Cohance Lifesciences is trading -0.01% lower at Rs 691.25 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 698.95 & 687.50. Cohance Lifesciences has given -38.09% in this year & -6.43% in the last 5 days. Cohance Lifesciences has TTM P/E ratio 102.73 as compared to the sector P/E of 29.66.There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 4 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 48.88 Crores in its last quarter.Listed peers of Cohance Lifesciences include Biocon (5.06%), Laurus Labs (0.35%), Suven Pharmaceuticals (-0.01%).The Mutual Fund holding in Cohance Lifesciences was at 16.49% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Cohance Lifesciences was at 6.51% in 30 Sep 2025. The FII holding has decreased from the last quarter.
Updated on Nov 12, 2025, 09:44 AM UTC
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Biocon | Bullish | 404.60 | 5.06 | 54,093.55 | 47.70 | 2.08 | 0.13 | 59.81 |
| Laurus Labs | Bullish | 989.35 | 0.35 | 53,440.10 | 129.29 | 9.15 | 0.16 | 15.82 |
| Suven Pharmaceuticals | Bearish | 691.25 | -0.01 | 26,454.52 | 96.40 | 15.12 | - | 10.36 |
| Ipca Laboratories | Neutral | 1,340.00 | 1.34 | 34,048.27 | 40.79 | 5.17 | 0.28 | 8.55 |
| Ajanta Pharma | Moderately Bullish | 2,573.10 | -0.17 | 32,115.41 | 35.77 | 8.67 | 2.05 | 0.92 |
| Meeting Date | Purpose |
|---|---|
| 2025-11-12 | Quarterly Results |
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
Cohance Lifesciences is trading at 691.25 as on Wed Nov 12 2025 09:40:30. This is -0.01% lower as compared to its previous closing price of 691.30.
The market capitalization of Cohance Lifesciences is 26454.52 Cr as on Wed Nov 12 2025 09:40:30.
The average broker rating on Cohance Lifesciences is Strong Buy. The breakup of analyst rating is given below -
The 52 wk high for Cohance Lifesciences is 1359.00 whereas the 52 wk low is 688.20
Cohance Lifesciences can be analyzed on the following key metrics -
Cohance Lifesciences reported a net profit of 267.87 Cr in 2025.
The Mutual Fund Shareholding was 16.49% at the end of 30 Sep 2025.